Literature DB >> 8876787

Observations and suggestions on antidementia drug development.

P Leber1.   

Abstract

Recent advances in the theoretical neurosciences have suggested a number of novel strategies that might be applied to prevent and/or retard the progression of Alzheimer disease. Whether or not these interventions will succeed cannot be determined on theoretical grounds, however; the value of each new stratagem must be evaluated in patients with Alzheimer disease. How best to conduct clinical studies of disease-modifying treatments remains a controversial subject. The author reviews and compares two clinical trial designs that may prove useful in assessing whether or not a putative treatment actually modifies the course of dementia.

Entities:  

Mesh:

Year:  1996        PMID: 8876787     DOI: 10.1097/00002093-199601031-00009

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  11 in total

1.  Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Joshua D Grill; Lijie Di; Po H Lu; Cathy Lee; John Ringman; Liana G Apostolova; Nicole Chow; Omid Kohannim; Jeffrey L Cummings; Paul M Thompson; David Elashoff
Journal:  Neurobiol Aging       Date:  2012-04-13       Impact factor: 4.673

2.  Frequency and impact of informant replacement in Alzheimer disease research.

Authors:  Joshua D Grill; Yan Zhou; Jason Karlawish; David Elashoff
Journal:  Alzheimer Dis Assoc Disord       Date:  2015 Jul-Sep       Impact factor: 2.703

3.  Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials.

Authors:  Jeffrey L Cummings
Journal:  Alzheimers Dement       Date:  2006-10       Impact factor: 21.566

4.  Advances in designs for Alzheimer's disease clinical trials.

Authors:  Jeffrey Cummings; Heath Gould; Kate Zhong
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

5.  Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats.

Authors:  Mireille Basselin; Henry N Nguyen; Lisa Chang; Jane M Bell; Stanley I Rapoport
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

6.  Disease-modifying benefit of Fyn blockade persists after washout in mouse Alzheimer's model.

Authors:  Levi M Smith; Rong Zhu; Stephen M Strittmatter
Journal:  Neuropharmacology       Date:  2017-11-27       Impact factor: 5.250

7.  A public health approach to clinical therapeutics in psychiatry: directions for new research.

Authors:  B D Lebowitz
Journal:  Dialogues Clin Neurosci       Date:  2000-09       Impact factor: 5.986

8.  Delayed-start analysis for demonstrating disease modification of solanezumab.

Authors:  Frank J Wolters; M Arfan Ikram
Journal:  Alzheimers Dement (N Y)       Date:  2015-10-19

Review 9.  Disease modification and Neuroprotection in neurodegenerative disorders.

Authors:  Jeffrey Cummings
Journal:  Transl Neurodegener       Date:  2017-09-26       Impact factor: 8.014

10.  Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.

Authors:  Jeffrey Cummings
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2020-10-28       Impact factor: 2.198

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.